Skip to main content

Purification and Characterization of Low-n Tau Oligomers

  • Protocol
  • First Online:
Amyloid Proteins

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1779))

Abstract

Deposition of Tau aggregates in patient’s brains is a hallmark of several neurodegenerative diseases collectively called Tauopathies. One of the most studied Tauopathies is Alzheimer disease (AD) in which Tau protein aggregates into filaments and coalesces into neurofibrillary tangles. The distribution of Tau filaments is a reliable indicator of the clinical stages of AD (Braak stages), but intermediate oligomeric assemblies of Tau are considered to be more directly toxic to neurons than late stage filaments. Studying the elusive role of Tau oligomers has been difficult because of their dynamic nature and paucity of methods to purify them in vitro. In this chapter, we describe methods to purify Tau oligomers to near homogeneity and to characterize them by hydrophobic interaction chromatography and biophysical methods such as fluorescence spectrophotometry, dynamic light scattering, atomic force microscopy, and others. Functional characterization includes the assessment of synapses and toxicity assays which show that oligomers can damage synapses locally but show little toxicity to neurons globally.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mandelkow EM, Mandelkow E (2012) Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2(7):a006247. https://doi.org/10.1101/cshperspect.a006247

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E (2000) Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A 97(10):5129–5134

    Article  Google Scholar 

  3. Mukrasch MD, Bibow S, Korukottu J, Jeganathan S, Biernat J, Griesinger C, Mandelkow E, Zweckstetter M (2009) Structural polymorphism of 441-residue tau at single residue resolution. PLoS Biol 7(2):e34. https://doi.org/10.1371/journal.pbio.1000034

    Article  PubMed  CAS  Google Scholar 

  4. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259

    Article  CAS  Google Scholar 

  5. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27(14):3650–3662. https://doi.org/10.1523/JNEUROSCI.0587-07.2007

    Article  PubMed  CAS  Google Scholar 

  6. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309(5733):476–481. https://doi.org/10.1126/science.1113694

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Scattoni ML, Gasparini L, Alleva E, Goedert M, Calamandrei G, Spillantini MG (2010) Early behavioural markers of disease in P301S tau transgenic mice. Behav Brain Res 208(1):250–257. https://doi.org/10.1016/j.bbr.2009.12.002

    Article  PubMed  CAS  Google Scholar 

  8. Van der Jeugd A, Hochgrafe K, Ahmed T, Decker JM, Sydow A, Hofmann A, Wu D, Messing L, Balschun D, D’Hooge R, Mandelkow EM (2012) Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol 123(6):787–805. https://doi.org/10.1007/s00401-012-0987-3

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R, Lane JR, Karydas AM, Kenet RO, Biernat J, Wang LS, Cotman CW, Decarli CS, Levey AI, Ringman JM, Mendez MF, Chui HC, Le Ber I, Brice A, Lupton MK, Preza E, Lovestone S, Powell J, Graff-Radford N, Petersen RC, Boeve BF, Lippa CF, Bigio EH, Mackenzie I, Finger E, Kertesz A, Caselli RJ, Gearing M, Juncos JL, Ghetti B, Spina S, Bordelon YM, Tourtellotte WW, Frosch MP, Vonsattel JP, Zarow C, Beach TG, Albin RL, Lieberman AP, Lee VM, Trojanowski JQ, Van Deerlin VM, Bird TD, Galasko DR, Masliah E, White CL, Troncoso JC, Hannequin D, Boxer AL, Geschwind MD, Kumar S, Mandelkow EM, Wszolek ZK, Uitti RJ, Dickson DW, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Alzheimer’s Disease Genetics C, Ross OA, Rademakers R, Schellenberg GD, Miller BL, Mandelkow E, Geschwind DH (2012) Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer’s diseases. Hum Mol Genet 21(15):3500–3512. https://doi.org/10.1093/hmg/dds161

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R (2010) Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49(47):10039–10041. https://doi.org/10.1021/bi1016233

    Article  PubMed  CAS  Google Scholar 

  11. Kaniyappan S, Chandupatla RR, Mandelkow EM, Mandelkow E (2017) Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability. Alzheimers Dement. https://doi.org/10.1016/j.jalz.2017.04.002

  12. Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, Ward S, Reyes JF, Philibert K, Glucksman MJ, Binder LI (2011) Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem 286(26):23063–23076. https://doi.org/10.1074/jbc.M111.237974

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R (2011) Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener 6:39. https://doi.org/10.1186/1750-1326-6-39

    Article  PubMed  PubMed Central  Google Scholar 

  14. Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Schonig K, Bujard H, Mandelkow E, Zhou L, Rune G, Mandelkow EM (2008) The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci 28(3):737–748. https://doi.org/10.1523/JNEUROSCI.2824-07.2008

    Article  PubMed  CAS  Google Scholar 

  15. Pickhardt M, Biernat J, Hubschmann S, Dennissen FJA, Timm T, Aho A, Mandelkow EM, Mandelkow E (2017) Time course of Tau toxicity and pharmacologic prevention in a cell model of Tauopathy. Neurobiol Aging 57:47–63. https://doi.org/10.1016/j.neurobiolaging.2017.04.022

    Article  PubMed  CAS  Google Scholar 

  16. von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM, Mandelkow E (2001) Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem 276(51):48165–48174. https://doi.org/10.1074/jbc.M105196200

    Article  Google Scholar 

  17. Barghorn S, Biernat J, Mandelkow E (2005) Purification of recombinant tau protein and preparation of Alzheimer-paired helical filaments in vitro. Methods Mol Biol 299:35–51

    PubMed  CAS  Google Scholar 

  18. Gasymov OK, Glasgow BJ (2007) ANS fluorescence: potential to augment the identification of the external binding sites of proteins. Biochim Biophys Acta 1774(3):403–411. https://doi.org/10.1016/j.bbapap.2007.01.002

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Wegmann S, Muller DJ, Mandelkow E (2012) Investigating fibrillar aggregates of Tau protein by atomic force microscopy. Methods Mol Biol 849:169–183. https://doi.org/10.1007/978-1-61779-551-0_12

    Article  PubMed  CAS  Google Scholar 

  20. Schweers O, Mandelkow EM, Biernat J, Mandelkow E (1995) Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc Natl Acad Sci U S A 92(18):8463–8467

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Gasymov OK, Abduragimov AR, Glasgow BJ (2007) Molten globule state of tear lipocalin: ANS binding restores tertiary interactions. Biochem Biophys Res Commun 357(2):499–504. https://doi.org/10.1016/j.bbrc.2007.03.186

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Eckhard Mandelkow .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Kaniyappan, S., Chandupatla, R.R., Mandelkow, E. (2018). Purification and Characterization of Low-n Tau Oligomers. In: Sigurdsson, E., Calero, M., Gasset, M. (eds) Amyloid Proteins. Methods in Molecular Biology, vol 1779. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7816-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7816-8_8

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7815-1

  • Online ISBN: 978-1-4939-7816-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics